Effect of esketamine on postoperative depression in women with breast cancer and preoperative depressive symptoms: The EASE randomized trial
Primary resultResult — go to the resultOdds ratio 2.4 95 % CI 0.9–6.6Authors' conclusion
Intraoperative administration of 0.25 mg/kg esketamine did not significantly improve the fraction of depressed women having breast cancer patients who had a 50 % reduction in their depression scores at 3 days postoperatively.
Study context
- Population
- Women 18–65 years scheduled for elective breast cancer surgery with preoperative depressive symptoms (Montgomery-Åsberg score ≥12)104 in ITT analysis
- Participants
- 108 women
- Comparison
- Intraoperative esketamine 0.25 mg/kg vs saline placebo
- Esketaminen = 54
- Salinen = 54reference
- Primary endpoint
- Fraction of patients with ≥50 % reduction in Montgomery-Åsberg depression score
- Follow-up
- Within 3 postoperative days
Methodological detailsprospective, single-centre, double-blind, placebo-controlled
- Prospective
- Single-centre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Odds ratio
2.4
95 % CI 0.9–6.6
P = 0.087
By group
Esketamine vs Saline
OR 2.4 (95 % CI 0.9–6.6); P = 0.087
Secondary outcomes
| Outcome | Mean difference (95 % CI) | P value | |
|---|---|---|---|
| Decrease in Montgomery-Åsberg score from baseline | - 2.5 (−4.5 to −0.6) | P = 0.010 | |
| −6−4−202Difference (linear scale) |
Montgomery-Åsberg depression scores · postoperative days 1 to 5
- Nearly a factor-of-two and significantly lower with esketamine
Other secondary outcomes (remission, severe pain, anxiety)
- No significant effect of esketamine
Original publication
Effect of esketamine on postoperative depression in women with breast cancer and preoperative depressive symptoms: The EASE randomized trial. J Clin Anesth. Published 27 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →